Is there a healthy future for Big Pharma?

The third Green Templeton Lecture 2009 explores how, by harnessing innovation to meet unmet medical needs, pharma companies can deliver significant value to patients, payers and shareholders. The Green Templeton Lectures 2009 explored the theme 'Addicted to Big Pharma? Reconcilin ...  Show more

This lecture will explore, from a historical perspective, the relationship between an emerging pharmaceutical industry, the establishment of drug regulatory authorities, and - most recently - the development of health technology assessment. 

China is fast becoming a major player in the global pharmaceutical and biotech industries. Once focused primarily on generic and me-too drugs, Chinese companies are now making headlines with innovative breakthroughs in oncology and gene therapy. Foreign investors are taking notic ...  Show more

Private markets have grown significantly over the past few years, fueled by scientific breakthroughs and technological innovation. Our experts discuss biotechnology, artificial intelligence and healthcare valuation trends, how venture capitalists and startups are navigating the c ...  Show more

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How ...  Show more